Novo Nordisk's Buyback Machine Keeps Rolling as FDA Stalls Denecimig and Deutsche Bank Stays Bearish

Deutsche Bank cut its Novo Nordisk price target to DKK 225, keeping Sell, as an FDA review of Denecimig slips and investors await Nov 4 nine-month results.

Novo Nordisk finds itself pulled in two directions at once. On one side sits a pipeline delivering genuinely encouraging clinical results; on the other, a regulatory calendar that has slipped and a sell-side community that refuses to budge on its caution. The Danish drugmaker's stock was quoted at EUR 33.58 on Thursday, down 1.4%, extending a soft stretch that has left investors hunting for signs of a durable floor.

Deutsche Bank Holds the Line

The most recent nudge to sentiment came from Deutsche Bank Research, which on Wednesday trimmed its price target on the shares to DKK 225 from DKK 245 while keeping its Sell rating intact. The analysts pointed to data presented at the EASD annual meeting, which they read as mildly negative, citing head-to-head comparisons across the study programs on display. Those conference findings had already been stirring debate in the market for roughly a week before the note landed.

That skepticism matters more than it once did. Clinical wins that would have been celebrated outright during the early enthusiasm for modern obesity therapies are now subjected to far closer scrutiny, and the burden has shifted onto management to prove clear clinical differentiation rather than simply claim leadership. High valuation multiples no longer survive on narrative alone — if the company cannot demonstrate where its core products genuinely separate from rivals, the durability of future earnings comes into question.

A Regulatory Pause With No New Date

Adding to the operational to-do list is the ongoing FDA review of Denecimig, Novo's hemophilia A candidate. According to Reuters, the agency has extended its assessment because remediation work at a manufacturing site is still underway. No revised decision timeline was offered.

Novo has stressed that the holdup does not affect its financial guidance for 2026, and no safety or efficacy deficiencies were flagged. Pending approval, the company still aims for a US launch in the first half of 2027. Even so, the episode is a reminder of how much can go wrong inside complex production chains — and how little visibility regulators provide when they pause.

Liver Fat and a Pill That Sheds Pounds

Where the science has delivered, it has delivered convincingly. A detailed readout of the STEP-UP trial, released on October 1, showed that among 55 participants with obesity and without diabetes, mean liver fat fell from 8.8% at baseline to 3.1% at week 72 on semaglutide. Nearly every participant who started with elevated levels dropped below the 5% threshold considered clinically concerning — 23 of the 26 in that subgroup.

The oral route offers a second avenue. Real-world data from the OCTANE study found that patients switching from injectable GLP-1 therapies to the Wegovy pill lost an average of 4.1% of body weight after three months. A tablet formulation could open the door to patients who reject injections outright, a population that has so far been difficult to reach.

Such results are central to Novo's effort to frame its compounds as more than weight-loss drugs, and they arrive alongside external deals that secure access to the next generation of molecules.

Hengrui Deal and the Buyback Ledger

Roughly a week ago, Novo struck a partnership with Jiangsu Hengrui Pharmaceuticals, acquiring worldwide rights to develop and commercialize the candidate HRS-1596 outside mainland China, Hong Kong, Macau and Taiwan. The agreement carries a USD 300 million upfront payment, with milestone payments that could lift the total to as much as USD 2.6 billion, plus royalties on top.

Funding that ambition is a buyback program authorized at up to DKK 15 billion over twelve months, launched in February. By early October, Novo had repurchased more than 36.6 million of its own B shares. The repurchases support earnings per share and telegraph management's confidence in its own earnings power, even as capital continues to flow toward development.

WHO Guidance and the Reimbursement Question

Broader policy shifts cut both ways. The World Health Organization has issued guidelines for managing obesity in adolescents aged 10 to 19, including pharmacological treatment — a development that widens the addressable population. Against that, reimbursement systems and pricing negotiations across key markets remain an open question for mid-term pricing, and the competitive field in metabolic therapies is only getting more crowded.

November 4 Is the Next Real Test

The next hard catalyst is set for November 4, 2026, when management reports results for the first nine months. If revenue growth in the core segments meets expectations and the board holds to its full-year targets, the recent lows could prove a workable support level. Should confidence in the expansion story crack, or should the interim figures reveal margin pressure from the competitive fight, the existing downtrend could pick up fresh momentum. Investors now face a straightforward choice: treat the valuation discount as an entry point, or wait for the nine-month numbers to settle the argument.